Fernando
Lecanda Cordero
Profesional Investigador
Stanford University School of Medicine
Stanford, Estados UnidosPublicacions en col·laboració amb investigadors/es de Stanford University School of Medicine (7)
2023
-
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 6, pp. 1137-1154
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
2020
-
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas
Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895
2017
-
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
Nature Communications, Vol. 8
2015
-
Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types
Journal of the National Cancer Institute, Vol. 107, Núm. 12
2011
-
Tumor-stromal interactions of the bone microenvironment: In vitro findings and potential in vivo relevance in metastatic lung cancer models
Clinical and Experimental Metastasis, Vol. 28, Núm. 8, pp. 779-791
2008
-
A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism
Cancer Research, Vol. 68, Núm. 7, pp. 2275-2285